Trever Bivona
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
The serine/threonine kinase BRAF is frequently mutated in several tumor types, including melanoma and non-small cell lung cancer (NSCLC). Oncogenic BRAF mutations can be classified as Class I, II, or III owing to differences in underlying oncogenic mechanisms. While there are approved targeted therapies for BRAF Class I mutants, there are no approved targeted therapy strategies for Class II and Class III BRAF mutated cancers. By leveraging analysis of a large, real world circulating tumor DNA (ctDNA) profiling database, we highlight a significant subset of NSCLC patients whose tumors harbored Class II and Class III BRAF mutations. These mutations comprise ~65% of BRAF-mutant NSCLC cases, with Class II patients showing significantly worse clinical outcomes compared to Class I patients. In several preclinical tumor systems with Class II and III BRAF mutations, exarafenib, a novel type 2 pan-RAF inhibitor that binds RAF proteins irrespective of isoform or dimerization state, demonstrates robust anti-tumor activity. Initial clinical evaluation also showed promising activity in Class II BRAF-mutant NSCLC patients. Mechanistic studies reveal that exarafenib resistance involves adaptive rewiring from conventional oncogenic BRAF-dependent signaling to an ARAF-mediated bypass pathway, characterized by drug-induced ARAF-KSR1 scaffolding complexes that maintain MAPK signaling despite pan-RAF inhibitor treatment. This resistance is driven by upstream RTK activation and RAS-GTP accumulation, which specifically promotes complex assembly under drug treatment. Based on these insights, we identified MEK inhibition as a rational combination strategy that overcomes resistance by targeting the convergence point of both signaling pathways. The exarafenib plus binimetinib combination demonstrated superior efficacy in diverse preclinical models. This study establishes ARAF-KSR1 complex formation as a novel resistance mechanism to pan-RAF inhibition and provides mechanistic rationale for combination strategies with potential to address the unmet clinical need for BRAF Class II and III-mutated NSCLC.
Year:
2025
Therapy resistance is a significant cause of death in patients treated with targeted cancer therapy in diverse oncogene-driven cancers. A better understanding of resistance mechanisms can lay the foundation for improving existing and developing new therapies. A recent elegant study published in Nature Chemical Biology sheds light on a new resistance mechanism. The authors define a novel role for ARAF, a member of the RAF protein family (ARAF, BRAF, and CRAF), that is distinct from its previously understood role as a RAS effector and MEK protein kinase in the MAPK pathway. They describe how ARAF sequesters active RAS at the plasma membrane in phase-separated condensates to sustain signaling and prevent inactivation by the RAS GTPase-activating protein neurofibromin 1. This study underscores emerging roles for biomolecular condensates in cancer and highlights important implications for disrupting protein condensates to address treatment resistance to RAS (and RAS pathway)-targeted therapies. The study also illuminates evolutionary functional distinction between the RAF proteins and indicates unique biology for ARAF in normal physiology and disease.
Year:
2025
Photo-proximity labeling proteomics (PLP) methods have recently shown that the cell surface receptors can dynamically form lateral interactome networks. Here, we present a paired set of PLP workflows that simultaneously track neighborhood changes for oncogenic epidermal growth factor receptor (EGFR) with temporal resolution, both outside and inside of cells. We achieved this by augmenting the multiscale PLP workflow we call MultiMap, where three photo-probes with different labeling ranges were photo-activated by one photocatalyst, Eosin Y. By anchoring Eosin Y extracellularly and intracellularly on EGFR, we captured hundreds of proteins on both sides of the cell membrane that change in proximity to EGFR upon EGF activation. Neighbors engaged with EGFR within minutes to over an hour, reflecting dynamic interactomes during early, mid- and late-signaling including phosphorylation, internalization, degradation and transcriptional regulation. This rapid “photographic” labeling approach provides snapshots of signaling neighborhoods, revealing their dynamic nature, and potential for drug targeting.
Year:
2024
Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene and adapter protein multimers. While these assemblies are associated with oncogenic signaling, their role in drug response is unclear. Here, we use optogenetics and live-cell imaging to find that EML4-ALK assemblies suppress transmembrane receptor tyrosine kinase (RTK) signaling by sequestering RTK adapter proteins including GRB2 and SOS1. Furthermore, ALK inhibition, while suppressing oncogenic signaling, simultaneously releases the sequestered adapters and thereby resensitizes RTK signaling. Resensitized RTKs promote rapid and pulsatile ERK reactivation that originates from paracrine ligands shed by dying cells. Reactivated ERK signaling promotes cell survival, which can be counteracted by combination therapies that block paracrine signaling. Our results identify a regulatory role for RTK fusion assemblies and uncover a mechanism of tolerance to targeted therapies.
Year:
2024
Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of the central nervous system. We applied a lung cancer-specific sequencing panel (CAPP-Seq) to 81 CSF, blood, and tissue samples from 24 lung cancer patients who underwent lumbar puncture (LP) for suspected leptomeningeal disease (LMD). A subset of the cohort ( N = 12) participated in a prospective trial of osimertinib for refractory LMD in which serial LPs were performed before and during treatment. CSF-tDNA variant allele fractions (VAFs) were significantly higher than plasma circulating tumor DNA (ctDNA) VAFs (median CSF-tDNA, 32.7%; median plasma ctDNA, 1.8%; P < 0.0001). Concentrations of tumor DNA in CSF and plasma were positively correlated (Spearman’s ρ, 0.45; P = 0.03). For LMD diagnosis, cytology was 81.8% sensitive and CSF-tDNA was 91.7% sensitive. CSF-tDNA was also strongly prognostic for overall survival (HR = 7.1; P = 0.02). Among patients with progression on targeted therapy, resistance mutations, such as EGFR T790M and MET amplification, were common in peripheral blood but were rare in time-matched CSF, indicating differences in resistance mechanisms based on the anatomic compartment. In the osimertinib cohort, patients with CNS progression had increased CSF-tDNA VAFs at follow-up LP. Post-osimertinib CSF-tDNA VAF was strongly prognostic for CNS progression (HR = 6.2, P = 0.009). Detection of CSF-tDNA in lung cancer patients with suspected LMD is feasible and may have clinical utility. CSF-tDNA improves the sensitivity of LMD diagnosis, enables improved prognostication, and drives therapeutic strategies that account for spatial heterogeneity in resistance mechanisms.
Year:
2024
Beyond lipid membrane compartments, cells including cancer cells utilize various membraneless compartments, often termed biomolecular condensates, to regulate or organize key cellular processes underlying physiologic or pathologic phenotypes. In this commentary, the emergence of biomolecular condensation in cancer biology is highlighted, with a focus on key unanswered questions and with implications for improving the understanding of cancer pathogenesis and developing innovative cancer management strategies.
Year:
2024
Collaborators (16)
Jennifer A. Doudna
University of California
Wayne Ngo
University of California, Berkeley
Aaron Newman
Associate Professor
Stanford University
Ross A Okimoto
University of California
Tej D. Azad
Johns Hopkins University School of Medicine
Arash Ash Alizadeh
Professor of Medicine
Stanford University School of Medicine
Maximilian Diehn
Professor
Stanford University
James A Wells
-
Zhi Lin
Shanghai Jiao Tong University
Aadel A. Chaudhuri
Washington University School of Medicine
WEI WU
University of California, San Francisco
Bo Huang
University of California, San Francisco
Seema Nagpal
-
Robert C. Doebele
University of Colorado Anschutz Medical Campus
Young-wook Jun
Professor
University of California, San Francisco
Shumei Kato
University of California, San Diego
Make your next move.
Prepare your application
Review drafts before you send them.